Central nervous system neuropeptide Y signaling modulates VLDL triglyceride secretion.
OBJECTIVE
Elevated triglyceride (TG) is the major plasma lipid abnormality in obese and diabetic patients and contributes to cardiovascular morbidity in these disorders. We sought to identify novel mechanisms leading to hypertriglyceridemia. Resistance to negative feedback signals from adipose tissue in key central nervous system (CNS) energy homeostatic circuits contributes to the development of obesity. Because triglycerides both represent the largest energy depot in the body and are elevated in both the plasma and adipose in obesity and diabetes, we hypothesized that the same neural circuits that regulate energy balance also regulate the secretion of TGs into plasma.


METHODS
In normal fasting rats, the TG secretion rate was estimated by serial blood sampling after intravascular tyloxapol pretreatment. Neuropeptide Y (NPY) signaling in the CNS was modulated by intracerebroventricular injection of NPY, receptor antagonist, and receptor agonist.


RESULTS
A single intracerebroventricular injection of NPY increased TG secretion by 2.5-fold in the absence of food intake, and this was determined to be VLDL by fast performance liquid chromatography (FPLC). This effect was recapitulated by activating NPY signaling in downstream neurons with an NPY-Y5 receptor agonist. An NPY-Y1 receptor antagonist decreased the elevated TGs in the form of VLDL secretion rate by 50% compared with vehicle. Increased TG secretion was due to increased secretion of VLDL particles, rather than secretion of larger particles, because apolipoprotein B100 was elevated in FPLC fractions corresponding to VLDL.


CONCLUSIONS
We find that a key neuropeptide system involved in energy homeostasis in the CNS exerts control over VLDL-TG secretion into the bloodstream.
Stafford
John M
JM
Division of Diabetes, Endocrinology, and Metabolism, Department of Internal Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Yu
Fang
F
Printz
Richard
R
Hasty
Alyssa H
AH
Swift
Larry L
LL
Niswender
Kevin D
KD
D000214:Acyl Coenzyme A / Q000378:metabolism; D000818:Animals; D002552:Cerebral Ventricles / Q000187:drug effects / Q000502:physiology*; D002784:Cholesterol / Q000097:blood; D005934:Glucagon / Q000097:blood; D007276:Injections, Intraventricular; D007328:Insulin / Q000097:blood; D020738:Leptin / Q000097:blood; D008074:Lipoproteins / Q000378:metabolism; D008079:Lipoproteins, VLDL / Q000187:drug effects / Q000378:metabolism*; D008099:Liver / Q000187:drug effects / Q000502:physiology; D008297:Male; D009478:Neuropeptide Y / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D020318:Rats, Long-Evans; D015398:Signal Transduction; D014280:Triglycerides / Q000097:blood* / Q000378:metabolism*
D000214:Acyl Coenzyme A; D007328:Insulin; D020738:Leptin; D008074:Lipoproteins; D008079:Lipoproteins, VLDL; D009478:Neuropeptide Y; D014280:Triglycerides; C030106:very low density lipoprotein triglyceride; D005934:Glucagon; D002784:Cholesterol